SSY Group (HKG:2005) obtained registration approvals for Bilastine and Sodium Picosulfate from China's National Medical Products Administration to become bulk drugs for preparations on the market, a Thursday Hong Kong bourse filing said.
Bilastine is mainly used for the symptomatic treatment of urticaria, while sodium picosulfate is used to cleanse the colon before surgical examination.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments